Kedi-B (02487.HK) announced that the results of its Phase III clinical trials in china for the androgenetic alopecia treatment product CU-40102 and CU-30101 for epidermal skin surgery were presented at the National Cosmetic Dermatology Conference (CDA annual meeting). Among them, the total hair count and terminal hair count in the target area of baldness for CU-40102 group significantly improved compared to the baseline and were better than the placebo group, achieving the primary endpoint and major secondary endpoints, with efficacy starting to manifest from week 12. As for CU-30101, its clinical trial results indicated that CU-30101 has comparable analgesic efficacy to Pliaglis, achieving the primary endpoint.

The pharmaceutical market approval applications for both products have been accepted by the National Medical Products Administration this year. (vc/u)

~